The PSA nadir that indicates potential cure after radiotherapy for prostate cancer-Reference-Cited by-同舟云学术

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

Published:1997-05 Issue:3 Volume:49 Page:322-326
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Critz Frank A.,Keith Levinson A.,Hamilton Williams W.,Holladay David A.,Holladay Clinton T.,Klein Eric A.,Kupelian Patrick J.

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. The periurethral glands do not significantly influence the serum prostate specific antigen concentration;Oesterling;J Urol,1996

2. The clinical usefulness of prostate specific antigen: update 1994;Partin;J Urol,1994

3. The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay;Takayama;J Urol,1993

4. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome;Zagars;Urology,1995

5. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma;Stock;CA Cancer J Clin,1996

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers;The Prostate;2023-10-25

2. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT;BMC Urology;2022-12-12

3. Salvage Radiotherapy Plus Androgen Deprivation Therapy for High-Risk Prostate Cancer with Biochemical Failure after High-Intensity Focused Ultrasound as Primary Treatment;Journal of Clinical Medicine;2022-07-30

4. Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2021-03-10

5. Time to achieve a prostate-specific antigen nadir of ≤0.2 ng/mL and related factors after permanent prostate brachytherapy;Brachytherapy;2021-01